‘HIV-ending’ drug could be made for just $25 per patient a year, say researchers
Guardian2 days
FDA Approves Biannual HIV Prevention Shot
Above: A syringe in front of the logo of Gilead Sciences pharmaceutical company on April 4, 2025. Image copyright: Nikos Pekiaridis/NurPhoto/Getty Images
The Spin
Narrative A
Gilead's breakthrough represents the closest thing to an HIV vaccine available today. The twice-yearly injection eliminates daily pill adherence challenges that have hindered prevention, particularly among young women in sub-Saharan Africa where HIV rates remain high. Lenacapavir’s near 100% efficacy in preventing infections — and the potential for it to cost just $25 a year — could finally turn off the tap of new HIV cases globally.
Narrative B
Despite Gilead's breakthrough, the current pricing in the U.S. for lenacapavir remains a barrier to widespread access. While licensing agreements with generics offer some hope, the lack of licensing agreements in key regions like Latin America and parts of Eastern Europe could limit the drug’s global impact, leaving millions at risk and undermining its potential to turn the tide on the HIV epidemic.
Metaculus Prediction
Editor's Note
This story currently has limited reporting from right-wing sources. We will continue to monitor all major outlets and update our coverage as additional perspectives become available.